Amylyx is proud to announce that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]), for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the U.S.
FDA Approves RELYVRIO™ (previously known as AMX0035) for the treatment of adults with ALS in the U.S.
Amylyx initiates Phase 2 clinical trial of AMX0035 in Wolfram syndrome
Amylyx announced that the first participant has been dosed in the Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of Wolfram syndrome (WS). Topline results are anticipated in 2024.
In pursuit of more
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Driven by People
Latest News
Keep in touch
To stay up to date on Amylyx news, click subscribe.